← Beijing Sun Novo Pharmaceutical Research overview

Beijing Sun Novo Pharmaceutical Research vs Shanghai Fosun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Beijing Sun Novo Pharmaceutical Research Co Ltd (688621.CG)

Q3 2026
▲2▼1

Sunshine Nuohe Swings to Loss as Pipeline Advances

  • H1 2026 swing to net loss Sunshine Nuohe reported a first-half 2026 net loss of 24.4 million yuan, versus a 130 million yuan profit a year earlier, as revenue fell 27.81% to 426 million yuan. The absence of large out-licensing deals and pressure on pharma revenue drove the swing, weighing on the stock.

    The loss is the core financial result that directly pressures the share price.

  • STC009 injection wins clinical trial approval A subsidiary received regulatory clearance to begin human testing of STC009, a Class 1 innovative drug for secondary hyperparathyroidism. This milestone advances the pipeline and signals progress in the company's peptide drug platform, supporting future value.

    Clinical approval is a concrete pipeline win that can lift investor sentiment.

  • STC007 out-licensed and pipeline builds The interim report highlighted that self-developed STC007 for pruritus completed an out-licensing deal, STC008 for cancer cachexia is in trials, and multiple peptide, small nucleic acid, and CAR-T programs entered clinical stage. R&D spending rose to 20.54% of revenue, supporting long-term growth.

    Pipeline progress and out-licensing show the innovation strategy is delivering, a positive counterweight to the loss.

  • Controlling shareholder sells 5% stake Controlling shareholder Li Qian transferred 5% of the company to a fund at 41.56 yuan per share for 233 million yuan. Control is unchanged and the buyer locked up for 12 months, but the sale adds supply and may raise governance or confidence questions.

    The stake sale is a capital event that can affect supply and sentiment, though its impact is ambiguous.

August 2026
▲2▼1

Sunshine Nuohe Swings to Loss as Pipeline Advances

  • H1 2026 swing to net loss Sunshine Nuohe reported a first-half 2026 net loss of 24.4 million yuan, versus a 130 million yuan profit a year earlier, as revenue fell 27.81% to 426 million yuan. The absence of large out-licensing deals and pressure on pharma revenue drove the swing, weighing on the stock.

    The loss is the core financial result that directly pressures the share price.

  • STC009 injection wins clinical trial approval A subsidiary received regulatory clearance to begin human testing of STC009, a Class 1 innovative drug for secondary hyperparathyroidism. This milestone advances the pipeline and signals progress in the company's peptide drug platform, supporting future value.

    Clinical approval is a concrete pipeline win that can lift investor sentiment.

  • STC007 out-licensed and pipeline builds The interim report highlighted that self-developed STC007 for pruritus completed an out-licensing deal, STC008 for cancer cachexia is in trials, and multiple peptide, small nucleic acid, and CAR-T programs entered clinical stage. R&D spending rose to 20.54% of revenue, supporting long-term growth.

    Pipeline progress and out-licensing show the innovation strategy is delivering, a positive counterweight to the loss.

  • Controlling shareholder sells 5% stake Controlling shareholder Li Qian transferred 5% of the company to a fund at 41.56 yuan per share for 233 million yuan. Control is unchanged and the buyer locked up for 12 months, but the sale adds supply and may raise governance or confidence questions.

    The stake sale is a capital event that can affect supply and sentiment, though its impact is ambiguous.

Latest
▲2▼1

Sunshine Nuohe Swings to Loss as Pipeline Advances

  • H1 2026 swing to net loss Sunshine Nuohe reported a first-half 2026 net loss of 24.4 million yuan, versus a 130 million yuan profit a year earlier, as revenue fell 27.81% to 426 million yuan. The absence of large out-licensing deals and pressure on pharma revenue drove the swing, weighing on the stock.

    The loss is the core financial result that directly pressures the share price.

  • STC009 injection wins clinical trial approval A subsidiary received regulatory clearance to begin human testing of STC009, a Class 1 innovative drug for secondary hyperparathyroidism. This milestone advances the pipeline and signals progress in the company's peptide drug platform, supporting future value.

    Clinical approval is a concrete pipeline win that can lift investor sentiment.

  • STC007 out-licensed and pipeline builds The interim report highlighted that self-developed STC007 for pruritus completed an out-licensing deal, STC008 for cancer cachexia is in trials, and multiple peptide, small nucleic acid, and CAR-T programs entered clinical stage. R&D spending rose to 20.54% of revenue, supporting long-term growth.

    Pipeline progress and out-licensing show the innovation strategy is delivering, a positive counterweight to the loss.

  • Controlling shareholder sells 5% stake Controlling shareholder Li Qian transferred 5% of the company to a fund at 41.56 yuan per share for 233 million yuan. Control is unchanged and the buyer locked up for 12 months, but the sale adds supply and may raise governance or confidence questions.

    The stake sale is a capital event that can affect supply and sentiment, though its impact is ambiguous.

Shanghai Fosun Pharmaceutical Group Co Ltd (600196.CG)

Q3 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

August 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

Latest
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.